Shailender Bhatia, MD, discusses phase 3 ADAM trial data on relapse-free survival and safety with adjuvant avelumab in Merkel cell carcinoma.
Shailender Bhatia, MD
Advertisement
Articles by Shailender Bhatia, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Dr Rodriguez on the Rationale for Testing LAG-3/PD-1 Dual Blockade in Nonsquamous NSCLC
5